In a landmark deal announced this month, President Donald Trump negotiated dramatically lower costs for weight-loss drugs ...

A 2026 CMS proposed rule contains multiple provisions that will improve the transparency of hospital prices and support the ...

The Centers for Medicare and Medicaid Services hosted health tech leaders at a Health Tech Ecosystem Connectathon event in Washington, D.C. | On Thursday, the Centers for Medicare and Medicaid ...

The deal is with drugmakers Eli Lilly and Novo Nordisk to cut prices of their weight-loss drugs and expand Medicare coverage ...

Key Takeaways - CMS maintains its authority to impose Medicare reenrollment bars: CMS emphasizes its ability to apply reenrollment ...

The Centers for Medicare & Medicaid Services (“CMS”) recently finalized a Medicare payment rule with significant implications for life ...

A letter sent to Mission Hospital employees claims an on-site survey by the state has removed the hospital from being placed ...

The Trump administration is expected to announce deals with Eli Lilly and Novo Nordisk to cut prices of some weight loss ...

Medicare will cover GLP-1 weight loss drugs for specific patient groups, beginning in mid-2026, under a deal struck with drugmakers.

The two-month reprieve extends through January 2026. While some providers are restarting telehealth services, it remains ...

CMS is advancing a major step toward site-neutral payment reform in its proposed 2026 Hospital Outpatient Prospective Payment System rule, a move that could redefine how hospitals and ASCs collaborate ...

Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid beneficiaries. The prices of Ozempic and Wegovy will ...